Moderna Inc. News
Novavax Stock Slides As JPMorgan Slashes Price Target, Lowers Rating
JPMorgan analyst Eric Joseph slashed his price target on Novavax by more than $100, to $27 per share.
Goldman Sachs Lists Most Underweighted Value Stocks
Value stocks will gain whether inflation peaks or the Fed tightens enough to spark a recession, Goldman Sachs said.
Moderna Sues Pfizer, BioNtech For Covid Vaccine Patent Infringement
"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission," Moderna said.
Novavax Stock Plummets After Slashing 2022 Vaccine Sales Forecast
"I believe we were late to the market and US vaccination was driven by what was available and shown to work," said Novavax CEO Stanley Erck.
Biotech Can't Conquer the Lungs. Will These Stocks Succeed?
The lungs have evolved to keep things out. Can these biotech stocks get drugs in?
Novavax Stock Surges as FDA Panel Recommends EUA for Protein-Based Covid Vaccine
"The advisory committee's positive recommendation acknowledges the strength of our data and the importance of a protein-based Covid vaccine," said CEO Stanley Erck.
Ebay Tops BofA List of Companies with High Free Cash Flow
Bank of America put together a list of S&P 500 stocks with the highest free-cash-flow-to-enterprise value ratios.
Stock Market Today - 5/4: Dow Surges 930 Points As Powell Plays Down 75 Basis Point Rate Talk Following Fed Hike
Federal Reserve Chairman Jerome Powell, added a dovish caveat to the central bank's biggest rate hike in 22 years,, suggesting that core inflation may have peaked and that a 75 basis point rate hike is not being "actively considered" by policymakers.
Moderna Stock Active After Smashing Q1 Earnings Forecast, Affirming Vaccine Sales Forecast
"Today, we are reiterating our signed advanced purchase agreements for 2022 of $21 billion," said CEO Stéphane Bancel.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.